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Summary 
The interleukin  2 receptor ~  chain (IL-21~)  is preferentially expressed in natural killer (NK) 
cells, but is not detected in a majority of resting T  and B cells. We recently established a novel 
monoclonal antibody (mAb) to murine IL-2RB and examined in vivo the effect of the mAb 
in mice. We found that intraperitoneal injection of the anti-IL-2RB mAb into adult mice resulted 
in a selective in vivo elimination of splenic NK function in various mouse strains.  The reduction 
of NK cell function is associated with complete disappearance  of NKI.1 + cells in C57BL/6 mice. 
Other lymphocyte subsets in the thymus and spleen were uncompromised.  T  cell function was 
not affected by the mAb treatment as judged by allogeneic cytotoxic T cell induction. The single 
injection of anti-IL-2RB mAb caused a long-term elimination of splenic NK cells,  lasting for 
at least 5 wk.  We also found that  NK and/or  NK precursor cells become susceptible to the 
mAb treatment  only after birth,  suggesting  that functional maturation  of NK cells in terms 
of IL-2RB expression is a later event in the course of NK cell development. The use of the anti- 
IL-2RB mAb will be useful in defining  the physiological role of NK cells in host defense as 
well as dissecting their  developmental pathway in vivo. 
N 
'K cells are large granular lymphocytes (LGL) that express 
MHC-nonrestricted cytotoxic activity. Several lines of 
evidence indicate that the NK cell is responsible for eradica- 
tion of tumor cells (1, 2) and vitally infected cells (3), how- 
ever, roles of NK cells in immune defense remain to be fully 
elucidated. 
IL-2 is a major growth factor for mature NK cells (4, 5). 
Freshly  isolated  NK  cells  preferentially  express  IL-2RB, 
through which IL-2 plays a pivotal role in proliferation and 
induction of cytolytic activity (6). IL-2RB is also expressed 
in other cell types, such as fetal T cells expressing V'r5 TCR 
(7)  and  a subset of adult  CD8 +  T  cells (8).  We recently 
reported that in utero treatment of mice with a neutralizing 
mAb against  IL-2RB completely and selectively abrogates 
development of the Thy-1 + dendritic epidermal cell (Thy-1 + 
dEC),  which is a descendant of the IL-2RB + V3'5 TCR + 
cells (7). 
In the present study, we report that postnatal treatment 
of mice with the anti-IL-2RB mAb (a single intraperitoneal 
injection) causes a long-lasting  selective elimination  of NK 
cells. We also report that NK cells and/or NK precursor cells 
become sensitive to anti-IL-2RB mAb treatment after birth. 
Materials and Methods 
M/c~  Pregnant or male C57BL/6 and male C3H/He mice were 
purchased from Shizuoka Laboratory Animal Center (Hamamatsu, 
Japan). Institute of Cancer Research (ICR) nu/nu mice and SCID 
(C.B17 scid/scid) mice were obtained from Charles River Japan Inc. 
(Atsugi, Japan) and Nihon Clea Inc. (Tokyo, Japan), respectively. 
mAbs.  The mAbs used were as follows: TM-/~I (anti-IL-21L8 
[8]), PK136 (anti-NKl.1  [91), 145-2Cll (anti-CD3 [10]), H57-597 
(anti-cff~ TCR [11]), GL3 (anti-3'/~  TCR [12]), RM4-5 (anti- 
CD4 [Pharmingen, San Diego, CA]), 53-6.7 (anti-CD8 [13]), RA- 
3B2 (anti-B220  [14]), and M1/70 (anti-Mac-1 [15]). 
Antibody Treatment.  Adult mice were treated intraperitoneally 
with 1 mg of anti-IL-2RB mAb TM-B1  (rat IgG2b)  or control 
normal rat IgG (Sigma Chemical Co., St. Louis, MO) in 500/~1 
of PBS as indicated. In a separate series of experiments, antibody 
injection was performed by two different protocols as follows. For 
in  utero  treatment,  pregnant  C57BL/6  mice  were  given  in- 
traperitoneal injection of I mg of anti-Ib2RB mAb daily from day 
12 of gestation  until birth as previously described (7). For post- 
natal treatment,  neonatal mice were given a subcutaneous injec- 
tion of ,'~50/~g of anti-Ib2RB mAb three times a week, which 
was continued  until  analysis. Injection  volume  was "~50/~l/d. 
Normal rat  IgG was injected as a negative control in some ex- 
periments. 
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measured in a standard 4-h SXCr release assay (16). Briefly, 5  x 
103 52Cr-labeled YAC-1 cells were mixed with a varied number of 
spleen cells and incubated for 4 h in 200/zl of the culture medium 
(RPMI 1640 [ICN Biomedicals Inc., Costa Mesa, CA], 10% FCS 
[Cell Culture Laboratories, Cleveland, OH], 10 mM Hepes, 2 mM 
r-glutamine,  50 #M 2-ME,  100 U/ml penicillin, and 100/zg/ml 
streptomycin). Nylon wool-nonadherent  spleen cells (17) were used 
for a NK source in C57BL/6 mice. After incubation,  the radioac- 
tivity in 100 #I of supernatant was measured and percent cytotox- 
icity was determined.  Primary  CTL were induced by culture  of 
C57BL/6 mouse spleen cells (5  x  1@) with mitomycin C-treated 
BALB/C mouse spleen cells (2.5  x  106) for 4 d in 2 mt of the 
culture medium. The cytotoxicity was determined as above  by using 
P815 (H-2a), RL-malel  (H-2a), or EL-4 (H-2  b) cells as targets. 
Flow Cytometry.  Immunofluorescence and flow cytometric anal- 
ysis was performed as described (8). At least 10,000 cells per sample 
were  analyzed on  EPICS-CS  or  EPICS-Elite  flow  cytometers 
(Coulter  Electronics, Hialeah,  FL). 
Results and Discussion 
Selective Long-Term Elimination of NK Cells by an Anti-IL- 
2R~ mAb In Viwx  To evaluate the functional importance 
of IL-2R,8 expression in NK cells in vivo, adult mice were 
given an intraperitoneal injection of a function-blocking anti- 
IL-2RB  mAb  TM-B1  (8).  NK  activity  in  the  spleen  of 
antibody-treated mice was determined by using YAC-1 cells 
as a target.  We found that an intraperitoneal  injection with 
anti-IL-2RB mAb abrogated cytolytic activity of NK cells 
in various mouse strains, including C3H/He, C57BL/6, ICR 
nu/nu,  and SCID mice (Fig.  t). As shown in Fig.  1, C and 
D, a single intraperitoneal injection of t  mg of anti-IL-2R43 
mAb is sufficient for a profound reduction of NK activity 
in vivo. 
Flow  cytometric  analysis  was  performed  to  determine 
whether the reduction of NK activity was caused by func- 
tional  inactivation  or  elimination  of NK  cells  by  using 
C57BL/6 mice.  As shown in Fig.  2,  NK cells marked by 
expression  of NKI.1  alloantigen  were  almost  completely 
depleted in anti-IL-2RB-treated mice (Fig. 2 B), whereas they 
were readily detected in control IgG-treated mice (Fig. 2 A). 
Cells with lower levels of IL-2R~ expression as compared 
with NK cells were still present after anti-IL-2R,8 mAb treat- 
ment (Fig.  2 B). This cell population most likely represents 
CD8 +  T, cells,  since  it  lacks  NKI.1  antigen  expression. 
Asialo-GM1 + IL-2RB + cells were also depleted in anti-IL- 
2RB mAb-treated  SCID mice (data not  shown). 
Further investigation revealed that the depletion was NK 
cell specific.  First,  similar numbers of cells were recovered 
from the spleen of anti-IL-2RB mAb- or control IgG-treated 
mice, and various splenic lymphocytes subsets remained in- 
tact in the mice treated with anti-IL-2R~ mAb (Table 1). 
Second, lymphocyte composition in the thymus and lymph 
nodes were unaffected,  and intraepithelial  T  cells,  such as 
Thy-1 + dEC and intestinal intraepithelial T cells, were also 
unchanged  by this  anti-IL-2R~  mAb treatment  (data not 
shown). Third, as shown in Fig. 3, alloantigen-reactive CTL 
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Figure  1.  Treatment with anti-IL-2R~/mAb abrogates splenic NK cell 
activity in adult mice. Mice were injected with I mg of anti-lb2R,8 mAb 
TM-B1 (I) or normal rat lgG ([[]) in each treatment. Antibody treat- 
merit was performed three times every other day (.4 and B) or only once 
(C and D). NK activity was determined 2 d after the termination of anti- 
body treatment by using YAC-1 cells as a target. (A) C3H/He, (B) ICR 
nu/nu, (C) C57BL/6, and (D) SCID. 
were induced normally from the spleen of anti-IL-2RB mAb- 
treated mice. 
Next we performed flow cytometric analysis at various time 
points after the single mAb treatment to determine the du- 
ration  of the  NK  cell  depletion.  As  shown  in  Fig.  4, 
NKI.1 + IL-2RB + NK cells  were hardly  detectable in the 
spleen of the anti-IL-2RB-treated  mice up to 5 wk after a 
single injection of the mAb, indicating  that NK deficiency 
is long lasting.  Ongoing experiment indicates that there is 
no  sign  of the  recovery of NKI.I+IL-2RB +  cells  in  the 
spleen even 7 wk after the mAb injection (data not shown). 
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Figure 2.  Anti-IL-2RB mAb treatment depletes splenic  NK cells  in vivo. 
C57BL/6 mice were given a single intraperitoneal injection of Img of 
control normal rat  IgG (tl) or anti-IL-2RB mAb TM-~I (B). Nylon 
wool-nonadherent spleen cells  were incubated with a combination of FITC- 
conjugated PK136 (anti-NKl.1) and biotinylated TM-/31 (anti-Ib2RB) and 
stained with PE-conjugated streptavidin. Immunofluorescence was ana- 
lyzed on an EPICS-CS flow cytometer  (Coulter Electronics)  The per- 
centage of positively  stained  cells  is indicated  by the number  in each quadrant. 
1104  Selective  In Vivo Elimination of Natural Killer Cells in Mice Table  1.  Splenic Lymphocyte Subsets in Antibody-treated Mice 
Positive cells (n  =  3) 
Control  Anti-IL-2RB 
%  _+SD 
CD3 §  34.3  +  3.3  34.3  _+  4.6 
c~/3 TCR +  33.7  +  1.7  34.7  _+  3.7 
3'/~ TCR§  3.3  +  0.5  4.0  _+  0.8 
CD4 §  21.0  +_  0.8  22.3  +  3.1 
CD8 §  12.7  _+  0.9  12.7  +  1.2 
B220 §  51.7  +_  2.5  49.3  +  1.2 
Mac-1 §  3.3  _+  0.5  2.7  +_  0.9 
C57BL/6 mice were treated intraperitoneally  with 1 mg of anti-IL-2RB 
mAb (TM-B1)  or control IgG. 2 d after antibody treatment, spleen cells 
from the mice (n  =  3) were stained  with FITC-conjugated mAb and 
examined for the presence  of corresponding  markers  by an  EPICS-CS 
flow cytometer. Mean values of percentages  are  shown  _+  SD. 
NK cell depletion in vivo was also successfully accomplished 
by administering antibody to cell surface antigens expressed 
in NK cells, such as asialo-GM1  (18), NKI.1 (19, 20), and 
3.2.3 antigen (21). However, previous studies indicated that 
these antibodies caused only a short-term elimination of NK 
cells in vivo and that there was a substantial recovery of NK 
cells within 2 wk (18-21).  Although the molecular mecha- 
nism(s) of disappearance  of NK cells by anti-IL-2R43 mAb 
treatment is not precisely known at present, the long-lasting 
effect of anti-IL-2Rt3 mAb may suggest the possible involve- 
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Figure  3.  CTL induction from anti-IL-2RB  mAb-treated mice. Pri- 
mary CTL were induced by culture of spleen cells from the anti-IL-2RB 
mAb- (m)  or control normal IgG- ([~)  treated  C57BL/6 mice with 
mitomycin C-treated BALB/c mouse spleen cells for 4 d. The cytotoxicity 
was determined by using P815 (H-2a), Rbmalel (H-2d), or EL-4 (H-2  b) 
tumor cells as targets. 
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Long-term elimination of NK cells in vivo by a single injec-  Figure  4. 
tion of the anti-IL-2RB mAb. C57BL/6 mice were treated intraperitoneally 
with 1 mg of anti-Ib2RB mAb TM-B1  (rot) or control normal rat IgG 
(D).  NKI.I+IL-2RB+NK cells  in  the  spleen  from untreated  (O)  or 
antibody-treated  mice were monitored at indicated time points after anti- 
body treatment by flow cytometry as described in Fig.  2. 
ment of the IL-2/IL-2K system in postnatal development of 
NK progenitor cells in vivo. 
NK Cells Become Susceptible to Anti-IL-2R~ mAb Treatment 
after Birth.  A  striking reduction of NK activity with ad- 
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Postnatal but not in utero treatment with anti-IL-2R~  mAb 
eliminates NK cell activity.  In utero (A) or postnatal  (B) treatment was 
performed as described in Materials and Methods.  NK activity of nylon 
wool-nonadherent spleen cells from the C57BL/6 mice treated with (rot) 
or without ([[]) anti-IL-21~ mAb TM-/31 was determined by using YAC-1 
cells as a target at 6 wk of age. 
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the effect of in utero or postnatal  treatment  with  anti-IL- 
2RB mAb on NK cell development. In utero treatment was 
carried out by intraperitoneal injection of anti-IL-2RB mAb 
into pregnant C57BL/6 mice from day 12 of gestation until 
birth,  and postnatal  treatment  was by subcutaneous injec- 
tion of the mAb to neonatal mice three times a week, which 
was continued until analysis.  Cytolytic activity of NK cells 
in antibody-treated  mice was determined  at  6 wk of age. 
As shown in Fig. 5, the in utero treatment with anti-IL- 
2RB mAb did not reduce cytolytic activity of NK cells (Fig. 
5 A), whereas the postnatal treatment with the same mAb 
completely abrogated cytotoxicity of NK cells against YAC-1 
cells  (Fig.  5 B). Flow cytometric analysis  revealed  that  the 
in utero treatment did not alter development of NK cells in 
the spleen, whereas the postnatal treatment abolished the ap- 
pearance of NK cells  (data not  shown).  As previously de- 
scribed (7), the in utero treatment with the anti-IL-2RB mAb 
completely abrogated development of Thy-1 + dEC, whose 
precursor is IL-2R3 + fetal V75TCR § cells, indicating that 
this treatment  made saturating  levels of anti-IL-2R3 avail- 
able in  the  fetal  circulation  during  embryogenesis.  These 
findings altogether suggest that NK cell and/or NK precursor 
cells become sensitive to anti-IL-2R3 treatment after birth. 
Differential susceptibility of fetal and postnatal NK cells 
to anti-IL-2R3 mAb may suggest that induction or upregu- 
lation of IL-2R~ expression in the NK cell is a later event 
in the course of NK cell development. In fact, our prelimi- 
nary experiments showed that murine fetal liver of gestation 
day 14 contains a small proportion of NKI.1 + cells that ex- 
press considerably low levels of IL-2R~ as compared with 
adult  NKI.1 + cells  (T.  Tanaka,  unpublished  observation). 
Recently, it was proposed that NK and T cells have a common 
origin  (22-25).  If NK and  T  cells  do  share  the common 
pathway of development,  the IL-2R~ + cells found in fetal 
liver may be one of the candidates  of the "NK cell-T cell 
progenitor" Further biochemical and genetic studies are needed 
to elucidate the biological relevance  of this cell population 
in  NK cell and T  cell development. 
In the present study, we demonstrated a selective and long- 
lasting  elimination  of NK cells by a single intraperitoneal 
injection of anti-IL-2RB mAb. The IL-2RB mAb may also 
help  to generate animal  models to which various types of 
human cells can be readily transplanted. Although SCID mice 
have been used for this purpose, it has been reported  that 
a considerable proportion of human tumors actually fail to 
grow in SCID mice (26) possibly due to the NK activity 
observed in these mice (27, 28). We have observed that pretreat- 
ment of SCID mice with anti-IL-2RB mAb indeed favored 
the growth of freshly isolated adult T  cell leukemia cells in 
vivo (29). Therefore, we believe that anti-IL-2RB mAb will 
afford the means of effectively manipulating NK cells in vivo. 
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